Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

With the recent delay on TLando's approval, a conversation about the market potential if approved.

Ticker(s): LPCN, Clarus Therapeutics

Who's the expert?

A physician who is a high prescriber or testosterone products to patients and has followed the TLando story over the past few years.

Interview Questions
Q1.

Do you think TLando will be approved by the FDA in the coming weeks? 

Added By: joe_mccann
Q2.

If TLando is approved, what % of your patients currently on testosterone replacement therapy would you switch to TLando?

Added By: joe_mccann
Q3.

Is there a group of patients who currently should be receiving testosterone therapy, but do not? Would TLando be a good option for them?

Added By: joe_mccann
Q4.

Do you think the TMax excursion issue was likely resolved in this filing?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.